Why carry out this study?

The economic burden of hereditary transthyretin (ATTRv) amyloidosis in the USA has not been quantified

Previous studies of different variations of amyloidosis have shown significant healthcare utilization and costs associated with amyloidosis

This study’s aim was to estimate the costs and disease burden associated with ATTRv amyloidosis in a real-world setting

What was learned from the study?

Patients newly diagnosed with ATTRv amyloidosis have substantial healthcare utilization and costs in the first year, primarily the initial months, following diagnosis

Further research should examine later costs associated with disease progression and end-of-life care